Chronic myelogenous leukemia--update and future directions.

Kantarjian, H M; Deisseroth, A; Talpaz, M

Kantarjian, H M; Deisseroth, A; Talpaz, M.

Rev Invest Clin ; Suppl: 118-24, 1994 Apr.

Article in En | MEDLINE | ID: mdl-7886295

Subject(s)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Antineoplastic Agents/therapeutic use; Bone Marrow Transplantation; Clinical Trials as Topic; Combined Modality Therapy; Humans; Immunologic Factors/therapeutic use; Interferon-alpha/therapeutic use; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/mortality; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/physiopathology; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/therapy; Oncogenes; Prognosis; Risk Factors

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Myelogenous, Chronic, BCR-ABL Positive Type of study: Etiology_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Rev Invest Clin Journal subject: MEDICINA Year: 1994 Document type: Article Country of publication: Mexico

Search on Google

Add to My VHL

XML

PubMed Links